Label‑free quantitative proteomics of gastric high‑grade intraepithelial neoplasia

Lin,Nan; Lin,Liping; Huang,Xinxiang; Huang,Chaozhong; Gong,Jinrong

doi:10.3892/etm.2025.12883

Label‑free quantitative proteomics of gastric high‑grade intraepithelial neoplasia

Authors:
- Nan Lin
- Liping Lin
- Xinxiang Huang
- Chaozhong Huang
- Jinrong Gong
View Affiliations

Affiliations: Department of Gastroenterology, The Affiliated Hospital of Putian University, Putian, Fujian 351100, P.R. China
Published online on: May 13, 2025 https://doi.org/10.3892/etm.2025.12883
Article Number: 133
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Early detection and diagnosis are key to improving the survival rate and reducing the fatality rate linked to gastric cancer. The precancerous lesion of gastric cancer is referred to as gastric high‑grade intraepithelial neoplasia (HGIN). Both the sensitivity and specificity of current biomarkers that aid in the diagnosis of gastric HGIN are still relatively low. Furthermore, proteomic data on gastric HGIN are still scarce. The present study aimed to explore candidate protein biomarkers for gastric HGIN screening with proteomics and bioinformatics technology. A total of 10 serum samples were collected and categorized into two groups, i.e., the gastric HGIN and the healthy control groups. Label‑free quantification in conjunction with liquid chromatography with tandem mass spectrometry was employed to identify the probable biomarkers for gastric HGIN. Furthermore, differentially expressed proteins (DEPs) were quantified by proteomics analysis. In total, 1,192 distinct serum proteins were discovered between the gastric HGIN group and the healthy control group. DEPs were identified in the further analyses, utilizing a threshold of a 1.5‑fold difference in expression level (P<0.05) in comparison with the control group. There were 18 upregulated and 12 downregulated proteins in the gastric HGIN group in comparison with the control group. Bioinformatics analyses were performed using Gene Ontology and KEGG pathway enrichment analyses. The GO analysis revealed that the DEPs were enriched in biological processes such as ‘cellular’, ‘biological regulation’, ‘multicellular organismal’, ‘developmental’ and ‘reaction to stimulus processes’, localized to ‘cell’, ‘intracellular’ and ‘protein‑containing complex’, and involved in molecular functions such as ‘molecular function modulator’, ‘binding’ and ‘catalytic activity’. The KEGG pathway enrichment analysis manifested that the DEPs were predominantly enriched in ‘antigen processing and presentation’, ‘diabetic cardiomyopathy’, ‘Epstein‑Barr virus infection’, ‘herpes simplex virus 1 infection’, ‘human immunodeficiency virus 1 infection’ and ‘human cytomegalovirus infection’. In conclusion, the present data provide more biological information for the formation of gastric HGIN and clues for further research on the pathogenesis of early gastric cancer.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Wu D, Zhang P, Ma J, Xu J, Yang L, Xu W, Que H, Chen M and Xu H: Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 8:1576–1583. 2019.PubMed/NCBI View Article : Google Scholar
3	Liu K, Song S, Fu T, Liu Y, Zhang H, Yan M, He Z, Zhang W, Su H, Li Z, et al: Spatiotemporal trends in the incidence of gastrointestinal neoplasms in Wuwei City of Northwestern China from 1995 to 2016: A hospital-based retrospective observational study. Front Oncol. 11(712857)2021.PubMed/NCBI View Article : Google Scholar
4	Shetty A, Balaraju G, Shetty S and Pai CG: Diagnostic utility of alarm features in predicting malignancy in patients with dyspeptic symptoms. Indian J Gastroenterol. 40:183–188. 2021.PubMed/NCBI View Article : Google Scholar
5	Repetto O, Maiero S, Magris R, Miolo G, Cozzi MR, Steffan A, Canzonieri V, Cannizzaro R and De Re V: Quantitative proteomic approach targeted to fibrinogen β Chain in tissue gastric carcinoma. Int J Mol Sci. 19(759)2018.PubMed/NCBI View Article : Google Scholar
6	Machlowska J, Baj J, Sitarz M, Maciejewski R and Sitarz R: Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 21(4012)2020.PubMed/NCBI View Article : Google Scholar
7	Liu C, Wang Y, Li L, He D, Chi J, Li Q, Wu Y, Zhao Y, Zhang S, Wang L, et al: Engineered extracellular vesicles and their mimetics for cancer immunotherapy. J Control Release. 349:679–698. 2022.PubMed/NCBI View Article : Google Scholar
8	Liu Z, Su W, Ao J, Wang M, Jiang Q, He J, Gao H, Lei S, Nie J, Yan X, et al: Instant diagnosis of gastroscopic biopsy via deep-learned single-shot femtosecond stimulated Raman histology. Nat Commun. 13(4050)2022.PubMed/NCBI View Article : Google Scholar
9	Delgado-Guillena PG, Morales-Alvarado VJ, Elosua-González A, Murcia Pomares O, Pérez-Aisa A, Córdova H, Alcedo J, Calvet X and Fernández-Esparrach G: Gastroenterologists' attitudes on the detection and management of gastric premalignant conditions: Results of a nationwide survey in Spain. Eur J Cancer Prev. 30:431–436. 2021.PubMed/NCBI View Article : Google Scholar
10	Ray-Offor E and Obiorah CC: Helicobacter pylori and precancerous lesions of the stomach in a Nigerian Metropolis: A cohort study. Niger J Clin Pract. 21:375–379. 2018.PubMed/NCBI View Article : Google Scholar
11	Ji L, Liu Z, Zhou B, Cai Y, An F, Wang L, Lv Z, Xia M, Yang J, Yuan J, et al: Community-based pilot study of a screening program for gastric cancer in a Chinese population. Cancer Prev Res (Phila). 13:73–82. 2020.PubMed/NCBI View Article : Google Scholar
12	Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, Guo M, Lian X, Fan D and Zhang H: Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer. 17(737)2017.PubMed/NCBI View Article : Google Scholar
13	Toh J, Hoppe MM, Thakur T, Yang H, Tan KT, Pang B, Ho S, Roy R, Ho KY, Yeoh KG, et al: Profiling of gastric cancer cell-surface markers to achieve tumour-normal discrimination. BMJ Open Gastroenterol. 7(e000452)2020.PubMed/NCBI View Article : Google Scholar
14	Zhao J, Zhou R, Zhang Q, Shu P, Li H, Wang X, Shen Z, Liu F, Chen W, Qin J and Sun Y: Establishment of risk evaluation model of peritoneal metastasis in gastric cancer and its predictive value. Zhonghua Wei Chang Wai Ke Za Zhi. 20:47–52. 2017.PubMed/NCBI(In Chinese).
15	Wang Z, Mo TM, Tian L and Chen JQ: Gastrin-17 combined with CEA, CA12-5 and CA19-9 improves the sensitivity for the diagnosis of gastric cancer. Int J Gen Med. 14:8087–8095. 2021.PubMed/NCBI View Article : Google Scholar
16	Shi XJ, Wei Y and Ji B: Systems biology of gastric cancer: Perspectives on the omics-based diagnosis and treatment. Front Mol Biosci. 7(203)2020.PubMed/NCBI View Article : Google Scholar
17	Niclauss N, Gütgemann I, Dohmen J, Kalff JC and Lingohr P: Novel biomarkers of gastric adenocarcinoma: Current research and future perspectives. Cancers (Basel). 13(5660)2021.PubMed/NCBI View Article : Google Scholar
18	Shi F, Wu H, Qu K, Sun Q, Li F, Shi C, Li Y, Xiong X, Qin Q, Yu T, et al: Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer. Clin Proteomics. 15(18)2018.PubMed/NCBI View Article : Google Scholar
19	Yoo MW, Park J, Han HS, Yun YM, Kang JW, Choi DY, Lee JW, Jung JH, Lee KY and Kim KP: Discovery of gastric cancer specific biomarkers by the application of serum proteomics. Proteomics. 17(1600332)2017.PubMed/NCBI View Article : Google Scholar
20	Ahn HS, Sohn TS, Kim MJ, Cho BK, Kim SM, Kim ST, Yi EC and Lee C: SEPROGADIC-serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy. Sci Rep. 8(16892)2018.PubMed/NCBI View Article : Google Scholar
21	Rostami-Nejad M, Rezaei-Tavirani M, Mansouri V, Akbari Z and Abdi S: Impact of proteomics investigations on gastric cancer treatment and diagnosis. Gastroenterol Hepatol Bed Bench. 12 (Suppl 1):S1–S7. 2019.PubMed/NCBI
22	Panner Selvam MK, Finelli R, Agarwal A and Henkel R: Proteomics and metabolomics-current and future perspectives in clinical andrology. Andrologia. 53(e13711)2021.PubMed/NCBI View Article : Google Scholar
23	Liu D, Zhou L, Huang L, Zuo Z, Ho V, Jin L, Lu Y, Chen X, Zhao J, Qian D, et al: Microfluidic integrated capacitive biosensor for C-reactive protein label-free and real-time detection. Analyst. 146:5380–5388. 2021.PubMed/NCBI View Article : Google Scholar
24	Wu Y, Sang J, Zhou J and Fang Y: Comparative analysis of differences between preoperative endoscopic biopsy and postoperative pathological examination for diagnosis of gastric intraepithelial neoplasia. J Int Med Res. 49(300060521994929)2021.PubMed/NCBI View Article : Google Scholar
25	Fernández-Coto DL, Gil J, Hernández A, Herrera-Goepfert R, Castro-Romero I, Hernández-Márquez E, Arenas-Linares AS, Calderon-Sosa VT, Sanchez-Aleman MÁ, Mendez-Tenorio A, et al: Quantitative proteomics reveals proteins involved in the progression from non-cancerous lesions to gastric cancer. J Proteomics. 186:15–27. 2018.PubMed/NCBI View Article : Google Scholar
26	Huang A, Zhang M, Li T and Qin X: Serum proteomic analysis by tandem mass Tags (TMT) based quantitative proteomics in gastric cancer patients. Clin Lab. 64:855–866. 2018.PubMed/NCBI View Article : Google Scholar
27	Svoronos C, Tsoulfas G, Souvatzi M and Chatzitheoklitos E: Prognostic value of COL6A3 in pancreatic adenocarcinoma. Ann Hepatobiliary Pancreat Surg. 24:52–56. 2020.PubMed/NCBI View Article : Google Scholar
28	Liu W, Li L, Ye H, Tao H and He H: Role of COL6A3 in colorectal cancer. Oncol Rep. 39:2527–2536. 2018.PubMed/NCBI View Article : Google Scholar
29	Dai L, Li M, Zhang WL, Tang YJ, Tang YL and Liang XH: Fibroblasts in cancer dormancy: Foe or friend? Cancer Cell Int. 21(184)2021.PubMed/NCBI View Article : Google Scholar
30	Wang J and Pan W: The biological role of the collagen alpha-3 (VI) Chain and its cleaved C5 domain fragment endotrophin in cancer. Onco Targets Ther. 13:5779–5793. 2020.PubMed/NCBI View Article : Google Scholar
31	Lu Y, Kong X, Zhong W, Hu M and Li C: Diagnostic, therapeutic, and prognostic value of the thrombospondin family in gastric cancer. Front Mol Biosci. 8(647095)2021.PubMed/NCBI View Article : Google Scholar
32	Bessa C, Matos P, Jordan P and Gonçalves V: Alternative splicing: Expanding the landscape of cancer biomarkers and therapeutics. Int J Mol Sci. 21(9032)2020.PubMed/NCBI View Article : Google Scholar
33	Yu J, Zhang B, Zhang H, Qi Y and Wang Y, Wang W and Wang Y and Wang Y: E2F1-induced upregulation of long non-coding RNA LMCD1-AS1 facilitates cholangiocarcinoma cell progression by regulating miR-345-5p/COL6A3 pathway. Biochem Biophys Res Commun. 512:150–155. 2019.PubMed/NCBI View Article : Google Scholar
34	Huang Y, Li G, Wang K, Mu Z, Xie Q, Qu H, Lv H and Hu B: Collagen type VI alpha 3 Chain promotes epithelial-mesenchymal transition in bladder cancer cells via transforming growth factor β (TGF-β)/Smad pathway. Med Sci Monit. 24:5346–5354. 2018.PubMed/NCBI View Article : Google Scholar
35	Lee CW, Lin SE, Tsai HI, Su PJ, Hsieh CH, Kuo YC, Sung CM, Lin CY, Tsai CN and Yu MC: Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma. Oncol Lett. 15:559–567. 2018.PubMed/NCBI View Article : Google Scholar
36	Casal JI and Bartolomé RA: Beyond N-cadherin, relevance of cadherins 5, 6 and 17 in cancer progression and metastasis. Int J Mol Sci. 20(3373)2019.PubMed/NCBI View Article : Google Scholar
37	Valverde A, Povedano E, Ruiz-Valdepeñas Montiel V, Yáñez-Sedeño P, Garranzo-Asensio M, Rodríguez N, Domínguez G, Barderas R, Campuzano S and Pingarrón JM: Determination of cadherin-17 in tumor tissues of different metastatic grade using a single incubation-step amperometric immunosensor. Anal Chem. 90:11161–11167. 2018.PubMed/NCBI View Article : Google Scholar
38	Kang MH, Jeong GS, Smoot DT, Ashktorab H, Hwang CM, Kim BS, Kim HS and Park YY: Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1. Oncotarget. 8:98887–98897. 2017.PubMed/NCBI View Article : Google Scholar
39	Liu X, Huang Y, Yuan H, Qi X, Manjunath Y, Avella D, Kaifi JT, Miao Y, Li M, Jiang K and Li G: Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Cancer Lett. 454:204–214. 2019.PubMed/NCBI View Article : Google Scholar
40	Kmeid M, Lukose G, Hodge K, Cho D, Kim KA and Lee H: Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: A pathological, clinical and outcome study. Histopathology. 79:768–778. 2021.PubMed/NCBI View Article : Google Scholar
41	Altree-Tacha D, Tyrrell J and Haas T: CDH17 is a more sensitive marker for gastric adenocarcinoma than CK20 and CDX2. Arch Pathol Lab Med. 141:144–150. 2017.PubMed/NCBI View Article : Google Scholar
42	Jiang XJ, Lin J, Cai QH, Zhao JF and Zhang HJ: CDH17 alters MMP-2 expression via canonical NF-κB signalling in human gastric cancer. Gene. 682:92–100. 2019.PubMed/NCBI View Article : Google Scholar
43	Long ZW, Zhou ML, Fu JW, Chu XQ and Wang YN: Association between cadherin-17 expression and pathological characteristics of gastric cancer: A meta-analysis. World J Gastroenterol. 21:3694–3705. 2015.PubMed/NCBI View Article : Google Scholar
44	Thorne RF, Wang Y, Zhang Y, Jing X, Zhang XD, de Bock CE and Oliveira CS: Evaluating nuclear translocation of surface receptors: Recommendations arising from analysis of CD44. Histochem Cell Biol. 153:77–87. 2020.PubMed/NCBI View Article : Google Scholar
45	Chen C, Zhao S, Karnad A and Freeman JW: The biology and role of CD44 in cancer progression: Therapeutic implications. J Hematol Oncol. 11(64)2018.PubMed/NCBI View Article : Google Scholar
46	Xu H, Niu M, Yuan X, Wu K and Liu A: CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 9(36)2020.PubMed/NCBI View Article : Google Scholar
47	Senbanjo LT and Chellaiah MA: CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 5(18)2017.PubMed/NCBI View Article : Google Scholar
48	Nimmakayala RK, Batra SK and Ponnusamy MP: Unraveling the journey of cancer stem cells from origin to metastasis. Biochim Biophys Acta Rev Cancer. 1871:50–63. 2019.PubMed/NCBI View Article : Google Scholar
49	He Y, Xue C, Yu Y, Chen J, Chen X, Ren F, Ren Z, Cui G and Sun R: CD44 is overexpressed and correlated with tumor progression in gallbladder cancer. Cancer Manag Res. 10:3857–3865. 2018.PubMed/NCBI View Article : Google Scholar
50	Tongtawee T, Wattanawongdon W, Simawaranon T, Kaewpitoon S, Kaengpenkae S, Jintabanditwong N, Tangjanyatham P, Ratchapol W, Kangwantas K, Dechsukhum C, et al: Expression of cancer stem cell marker CD44 and its polymorphisms in patients with chronic gastritis, precancerous gastric lesion, and gastric cancer: A cross-sectional multicenter study in Thailand. Biomed Res Int. 2017(438482)2017.PubMed/NCBI View Article : Google Scholar
51	Wang L, Zuo X, Xie K and Wei D: The role of CD44 and cancer stem cells. Methods Mol Biol. 1692:31–42. 2018.PubMed/NCBI View Article : Google Scholar
52	Hettinghouse A, Liu R and Liu CJ: Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacol Ther. 181:34–48. 2018.PubMed/NCBI View Article : Google Scholar
53	Walsh RJ and Tan DSP: The role of immunotherapy in the treatment of advanced cervical cancer: Current status and future perspectives. J Clin Med. 10(4523)2021.PubMed/NCBI View Article : Google Scholar
54	Kure S, Chiba T, Ebina A, Toda K, Jikuzono T, Motoda N, Mitani H, Sugitani I, Takeuchi K and Ohashi R: Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis: A clinicopathological study of 1,139 cases with long-term follow-up. Endocr J. 69:273–281. 2022.PubMed/NCBI View Article : Google Scholar
55	Shimoda T, Wada R, Kure S, Ishino K, Kudo M, Ohashi R, Fujita I, Uchida E, Yoshida H and Naito Z: Expression of protein disulfide isomerase A3 and its clinicopathological association in gastric cancer. Oncol Rep. 41:2265–2272. 2019.PubMed/NCBI View Article : Google Scholar
56	Song D, Liu H, Wu J, Gao X, Hao J and Fan D: Insights into the role of ERp57 in cancer. J Cancer. 12:2456–2464. 2021.PubMed/NCBI View Article : Google Scholar
57	Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, Meheus F, Verhoeven RHA, Vignat J, Laversanne M, et al: The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 47(101404)2022.PubMed/NCBI View Article : Google Scholar